CO6220840A2 - Formulaciones para el tratamiento de cancer - Google Patents

Formulaciones para el tratamiento de cancer

Info

Publication number
CO6220840A2
CO6220840A2 CO09085583A CO09085583A CO6220840A2 CO 6220840 A2 CO6220840 A2 CO 6220840A2 CO 09085583 A CO09085583 A CO 09085583A CO 09085583 A CO09085583 A CO 09085583A CO 6220840 A2 CO6220840 A2 CO 6220840A2
Authority
CO
Colombia
Prior art keywords
solubility
compound
pharmaceutical composition
formula
pure water
Prior art date
Application number
CO09085583A
Other languages
English (en)
Spanish (es)
Inventor
Valeria Ossovskaya
Lingyun Li
Barry Sherman
Original Assignee
Bipar Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39350967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6220840(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bipar Sciences Inc filed Critical Bipar Sciences Inc
Publication of CO6220840A2 publication Critical patent/CO6220840A2/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO09085583A 2007-01-16 2009-08-14 Formulaciones para el tratamiento de cancer CO6220840A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88075507P 2007-01-16 2007-01-16

Publications (1)

Publication Number Publication Date
CO6220840A2 true CO6220840A2 (es) 2010-11-19

Family

ID=39350967

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09085583A CO6220840A2 (es) 2007-01-16 2009-08-14 Formulaciones para el tratamiento de cancer

Country Status (32)

Country Link
US (1) US20080176946A1 (https=)
EP (2) EP2476461A3 (https=)
JP (1) JP2010516626A (https=)
KR (1) KR20090113852A (https=)
CN (1) CN101668561A (https=)
AU (1) AU2008206294A1 (https=)
BR (1) BRPI0806590A2 (https=)
CA (1) CA2674600A1 (https=)
CO (1) CO6220840A2 (https=)
CR (1) CR10975A (https=)
CY (1) CY1113819T1 (https=)
DK (1) DK2121139T3 (https=)
DO (1) DOP2009000178A (https=)
EC (1) ECSP099577A (https=)
ES (1) ES2395690T3 (https=)
GB (1) GB2447796C (https=)
GT (1) GT200900201A (https=)
HR (1) HRP20120960T1 (https=)
IL (1) IL199682A0 (https=)
MA (1) MA34559B1 (https=)
MX (1) MX2009007596A (https=)
NZ (1) NZ579098A (https=)
PL (1) PL2121139T3 (https=)
PT (1) PT2121139E (https=)
RS (1) RS52633B (https=)
RU (2) RU2481830C2 (https=)
SG (1) SG178714A1 (https=)
SI (1) SI2121139T1 (https=)
SV (1) SV2009003335A (https=)
TN (1) TN2009000292A1 (https=)
UA (1) UA100852C2 (https=)
WO (1) WO2008089272A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7961081B2 (en) * 2003-05-22 2011-06-14 John Tomlienovic Anti-theft system and method
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
CA2615374A1 (en) 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
CN103169973A (zh) 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
US20140051737A1 (en) * 2011-05-10 2014-02-20 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
AU2013352369B2 (en) * 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
WO2017192618A1 (en) * 2016-05-02 2017-11-09 Symbios Technologies, Inc. Electrochemical plasma activated aqueous chemotherapeutics
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
WO2020246737A1 (ko) * 2019-06-04 2020-12-10 사회복지법인 삼성생명공익재단 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
GB2611315B (en) * 2021-09-29 2024-01-03 Siemens Healthcare Gmbh Method of operating a magnetic resonance scanner
EP4537108A1 (en) * 2022-06-10 2025-04-16 Dana-Farber Cancer Institute, Inc. Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0348655A (ja) * 1989-07-14 1991-03-01 Shionogi & Co Ltd プロスタグランジンｄ↓２類の安定化
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5232735A (en) * 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5652260A (en) * 1991-10-22 1997-07-29 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
US6008250A (en) * 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
WO1998045253A1 (en) * 1997-04-10 1998-10-15 Isotechnika, Inc. Activated iododerivatives for the treatment of cancer and aids
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
EP1348432A4 (en) * 2001-01-04 2005-08-10 Daiichi Seiyaku Co CYCLODEXTRIN-CONTAINING PHARMACEUTICAL COMPOSITION
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
UA83816C2 (ru) * 2003-01-14 2008-08-26 Тева Фармасьютикал Индастриз, Лтд ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法

Also Published As

Publication number Publication date
IL199682A0 (en) 2010-04-15
EP2121139A1 (en) 2009-11-25
RS52633B (sr) 2013-06-28
CR10975A (es) 2009-10-15
GB2447796B (en) 2009-03-04
ECSP099577A (es) 2009-10-30
CA2674600A1 (en) 2008-07-24
EP2476461A3 (en) 2012-10-24
US20080176946A1 (en) 2008-07-24
SI2121139T1 (sl) 2013-01-31
PT2121139E (pt) 2012-12-12
BRPI0806590A2 (pt) 2013-07-23
ES2395690T3 (es) 2013-02-14
SG178714A1 (en) 2012-03-29
HK1121697A1 (zh) 2009-04-30
GB2447796C (en) 2009-11-12
NZ579098A (en) 2012-07-27
EP2121139B1 (en) 2012-10-10
HK1137158A1 (en) 2010-07-23
TN2009000292A1 (en) 2010-12-31
HRP20120960T1 (hr) 2012-12-31
DK2121139T3 (da) 2013-01-14
RU2012151571A (ru) 2014-06-10
GB2447796A (en) 2008-09-24
PL2121139T3 (pl) 2013-03-29
GB0807263D0 (en) 2008-05-28
RU2009130599A (ru) 2011-02-27
WO2008089272A1 (en) 2008-07-24
SV2009003335A (es) 2010-02-05
UA100852C2 (ru) 2013-02-11
DOP2009000178A (es) 2009-10-31
CN101668561A (zh) 2010-03-10
MA34559B1 (fr) 2013-10-02
RU2481830C2 (ru) 2013-05-20
CY1113819T1 (el) 2016-07-27
MX2009007596A (es) 2009-08-13
AU2008206294A1 (en) 2008-07-24
KR20090113852A (ko) 2009-11-02
EP2476461A2 (en) 2012-07-18
GT200900201A (es) 2011-06-23
JP2010516626A (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
CO6220840A2 (es) Formulaciones para el tratamiento de cancer
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
CA2662517A1 (en) Treatment of cancer
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
SV2010003464A (es) Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
PE20220705A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
CL2008003651A1 (es) Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
AR076850A1 (es) Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa.
WO2007099162A3 (fr) Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques
AR058569A1 (es) Inhibidores de histona desacetilasa para mejorar la actividad de agentes antifungicos
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
NI200800008A (es) Métodos para la neuroprotección
AR067770A1 (es) Derivados de tiazol y ditiazol para el tratamiento de diabetes
CO6150149A2 (es) Compuestos azabiciclicos como inhibidfores de la recaptacion de monoaminas
AR083760A1 (es) Agentes antibacterianos y composiciones farmaceuticas
AR060427A1 (es) Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares
AR078632A1 (es) Compuestos esteroidales modificadores de la melanogenesis y sus usos
UY28821A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.

Legal Events

Date Code Title Description
FC Application refused